Pregnancy History, Oral Contraceptive Pills Consumption (OCPs), and Risk of Multiple Sclerosis: A Systematic Review and Meta‑Analysis

Mahsa Ghajarzadeh, Aida Mohammadi, Zahra Shahraki, Mohammad Ali Sahraian, Mehdi Mohammadifar

Abstract


Background: To estimate the pooled odds of oral contraceptive pills consumption (OCPs) use as well as pregnancy history and multiple sclerosis (MS) risk. Methods: We systematically searched PubMed, Embase, Scopus, Web of Science, Google scholar, and gray literature including references of the references as well as conference papers. The search strategy in PubMed was ((Oral contraceptive pills) OR OCP) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating) AND (gravidity) OR (pregnancy). Results: Four studies were included. The pooled odds of developing MS in women with pregnancy history compared with nulligravid women was 0.64 (95%CI = 0.53 − 0.78) (I2 = 0, P = 0.5), which means that pregnancy reduces the risk of MS by 36%. The pooled odds of OCP consumption and risk of MS were 1.09 (95% CI = 0.67 − 1.76). By comparing the pooled odds of OCP consumption and risk of MS according to the country of the origin, we found that the pooled odds in Iranian studies was 1.03 (95% CI = 0.31 − 3.45) and the pooled OR in studies that were conducted in the United States was 1.13 (95% CI = 0.65 − 1.98), which showed that the country of the origin was not the cause of heterogeneity. Conclusions: The results of this systematic review show that pregnancy history is a protective factor for MS development, whereas OCP use has no significant effect.

Keywords


Multiple sclerosis; oral contraceptive pills; pregnancy; risk

Full Text:

PDF

References


Ghajarzadeh M, Jalilian R, Sahraian MA, Moghadasi AN,

Azimi A, Mohammadifar M, et al. Pain in patients with multiple

sclerosis. Maedica 2018;13:125.

Ghajarzadeh M, Keshtkar AA, Azimi A, Sahraian MA,

Mohammadifar M, Ramagopalan SV. The effect of vitamin D

supplements on clinical and para‑clinical outcomes in patients

with multiple sclerosis: Protocol for a systematic review. JMIR

Res Protoc 2019;8:e12045. doi: 10.2196/12045.

Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J,

Pakdaman H. Multiple sclerosis in Iran: A demographic study of

,000 patients and changes over time. Eur Neurol 2010;64:331‑6.

Turk Boru U, Boluk C, Tasdemir M, Gezer T, Serim VA. Air

pollution, a possible risk factor for multiple sclerosis. Acta

Neurol Scand 2020;141:431‑7.

Eskandari G, Ghajarzadeh M, Yekaninejad MS, Sahraian MA,

Gorji R, Rajaei F, et al. Comparison of serum vitamin D level

in multiple sclerosis patients, their siblings, and healthy controls.

Iran J Neurol 2015;14:81‑5.

Whitacre CC. Sex differences in autoimmune disease. Nat

Immunol 2001;2:777‑80.

Salehi F, Abdollahpour I, Nedjat S, Sahraian MA, Memari A‑H,

Rahnama M, et al. Uncovering the link between reproductive

factors and multiple sclerosis: A case‑control study on Iranian

females. Mult Scler Relat Disord 2018;20:164‑8.

Azimi A, Hanaei S, Sahraian MA, Mohammadifar M,

Ramagopalan SV, Ghajarzadeh M. Age at menarche and risk of

multiple sclerosis (MS): A systematic review and meta‑analysis.

BMC Neurol 2019;19:1‑5.

Alonso Á, Jick SS, Olek MJ, Ascherio A, Jick H,

Hernán MA. Recent use of oral contraceptives and the risk of

multiple sclerosis. Arch Neurol 2005;62:1362‑5.

Hellwig K, Chen LH, Stancyzk FZ, Langer‑Gould AM. Oral

contraceptives and multiple sclerosis/clinically isolated syndrome

susceptibility. PloS One 2016;11:e0149094. doi: 10.1371/journal.

pone. 0149094.

D’hooghe M, Haentjens P, Nagels G, D’Hooghe T, De Keyser J.

Menarche, oral contraceptives, pregnancy and progression of

disability in relapsing onset and progressive onset multiple

sclerosis. J Neurol 2012;259:855‑61.

Lv Y‑B, Wang Y, Ma W‑G, Yan D‑Y, Zheng W‑L, Chu C,

et al. Association of renalase SNPs rs2296545 and rs2576178

with the risk of hypertension: A meta‑analysis. PLoS One

;11:e0158880. doi: 10.1371/journal.pone. 0158880.

Rejali M, Hosseini SM, Tabaee MSK, Etemadifar M. Assessing

the risk factors for multiple sclerosis in women of reproductive

age suffering the disease in Isfahan Province. Int J Prev Med

;7:58.

Holmqvist P, Hammar M, Landtblom A‑M, Brynhildsen J. Age

at onset of multiple sclerosis is correlated to use of combined

oral contraceptives and childbirth before diagnosis. Fertil Steril

;94:2835‑7.

Nielsen NM, Jørgensen KT, Stenager E, Jensen A, Pedersen BV,

Hjalgrim H, et al. Reproductive history and risk of multiple

sclerosis. Epidemiology 2011:546‑52.

Hedström A, Hillert J, Olsson T, Alfredsson L. Reverse causality

behind the association between reproductive history and MS.

Mult Scler 2014;20:406‑11.

Magyari M, Koch‑Henriksen N, Pfleger CC, Sørensen PS.

Reproduction and the risk of multiple sclerosis. Mult Scler

;19:1604‑9.

Whitacre CC, Reingold SC, O’Looney PA, Blankenhorn E,

Brinley F, Collier E, et al. A gender gap in autoimmunity: Task

force on gender, multiple sclerosis and autoimmunity. Science

;283:1277‑8.

American Association for the Advancement of Science. Sex

differences in autoimmune disease: Focus on multiple sclerosis.

Science 1999;283:1278.

Villard-Mackintosh L, Vessey MP. Oral contraceptives

and reproductive factors in multiple sclerosis incidence.

Contraception. 1993;47:161-8.

Thorogood M, Hannaford PC. The influence of oral

contraceptives on the risk of multiple sclerosis. Br J Obstet

Gynaecol 1998;105:1296‑9.

POSER S, Raun N, Wikström J, Poser W. Pregnancy, oral

contraceptives and multiple sclerosis. Acta Neurol Scand

;59:108‑18.

Kupershmidt L, Amit T, Bar‐Am O, Youdim MB, Blumenfeld Z.

The neuroprotective effect of Activin A and B: Implication for

neurodegenerative diseases. J Neurochem 2007;103:962‑71.